Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract LB-254: Efficiently targeting cancer stem cells requires tactical activation from their dormant state and subsequent exhaustion

Edward H. Lin, Xi C. He, Xiaowei Yan, Yanhong Deng, Raymond Yeung, Jian Gu, Stephen Curley, Jeff Haug, Anthony Blau, Xifeng Wu, Qiang Tian and Linheng Li
Edward H. Lin
1University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xi C. He
2Stowers Inst. for Medical Research, Kansas City, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Yan
3The Institute for Systems Biology, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanhong Deng
1University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond Yeung
1University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Gu
4M. D. Anderson Cancer Center, Houston, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Curley
4M. D. Anderson Cancer Center, Houston, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Haug
2Stowers Inst. for Medical Research, Kansas City, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Blau
1University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xifeng Wu
4M. D. Anderson Cancer Center, Houston, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiang Tian
3The Institute for Systems Biology, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linheng Li
2Stowers Inst. for Medical Research, Kansas City, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-LB-254 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Akin to normal tissue stem cells (NTSCs), cancer stem cells (CSCs) may have adopted dual active-dormant mechanisms to respectively sustain growth while eluding exhaustion from conventional chemotherapy such as 5-fluorouracil (5-FU). How to effectively target dual active-dormant CSCs while preserving NTSCs is essential to curing cancers. We compared the kinetic states of NTSCs in gut and bone marrow as well as leukemia stem cells following 5-FU treatment and found a narrow window of opportunity when forcibly activated dormant NTSC/CSCs can be targeted following depletion of proliferating progeny. Given that stemness factors predict poor overall survival (OS) in many cancers, we proposed a novel two-step ADAPT strategy_activate from dormancy and potentiate subsequent targeting_ in an attempt to synchronize cytotoxic effects of 5-FU on proliferating cells with stemness inhibitors targeting activated CSCs respectively. We applied the two-step protocol using capecitabine, an oral 5-FU prodrug, and celecoxib, a selective COX-2 inhibitor that is also a stemness inhibitor (it down-regulates LGR5/6, CD133, Oct4/Sox effectors, ALDH, CD24, Wnt, Sonic Hedghog) in patients with unresectable metastatic colorectal cancer. We found that the ADAPT strategy resulted in complete or near complete response rate in 27 patients with surgically unresectable metastatic colorectal cancer, especially if coupled with radiation. The median survival for this group of patients reached 92.7 months (95% CI, 53.5 months - not reached). Paradoxically, patients who had confirmed complete response without surgery but with long-term ADAPT therapy enjoyed 100% 5-year relapse free survival compared to 42% of patients who had undergone surgical resection of metastasis (p=0.04 log rank). Intriguingly, Celecoxib exerted many opposite biologic effects compared to 5-FU on cell cycle, apoptosis, DNA repair/synthesis, particularly stemness genes/pathways, and thus produced conflicting effect in short-term colon cancer cultures when combined with 5-FU. This observation potentially explains the 6 months gain in OS in the responding patients and the lack of OS for all patients in reported phase III BICC-C study that randomized Celecoxib vs placebo with 5FU based chemotherapy.. Thus, optimal ADAPT strategy to target CSCs requires initial cytoreduction of proliferating progeny and activation of dormant/drug-resistant CSCs, and subsequent cyclical exhaustion via long-term exposure to stemness inhibitors along with intermittent cytotoxic agents such as 5-FU.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-254.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-254: Efficiently targeting cancer stem cells requires tactical activation from their dormant state and subsequent exhaustion
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract LB-254: Efficiently targeting cancer stem cells requires tactical activation from their dormant state and subsequent exhaustion
Edward H. Lin, Xi C. He, Xiaowei Yan, Yanhong Deng, Raymond Yeung, Jian Gu, Stephen Curley, Jeff Haug, Anthony Blau, Xifeng Wu, Qiang Tian and Linheng Li
Cancer Res April 15 2010 (70) (8 Supplement) LB-254; DOI: 10.1158/1538-7445.AM10-LB-254

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-254: Efficiently targeting cancer stem cells requires tactical activation from their dormant state and subsequent exhaustion
Edward H. Lin, Xi C. He, Xiaowei Yan, Yanhong Deng, Raymond Yeung, Jian Gu, Stephen Curley, Jeff Haug, Anthony Blau, Xifeng Wu, Qiang Tian and Linheng Li
Cancer Res April 15 2010 (70) (8 Supplement) LB-254; DOI: 10.1158/1538-7445.AM10-LB-254
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-304: Discovery of chemical probe CCT251236: An orally bioavailable efficacious pirin ligand from an HSF1 phenotypic screen
  • Abstract LB-302: Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma
  • Abstract LB-246: Detection of circulating tumor DNA in early stage cancers
Show more 3

Late-Breaking Poster Presentations - Cancer Stem Cells

  • Abstract LB-189: A role of Notch2 in quiescence of mammary stem/progenitor cells
  • Abstract LB-203: Mathematical modeling of the dynamic interaction between cancers stem cells and non-stem cancer cells and its potential clinical implication
  • Abstract LB-191: Glioblastomas can originate from neurons in the CNS
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement